A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Phase 3
200
about 2.8 years
18–63
81 sites in AL, AR, AZ +24
What this study is about
This trial is testing whether upadacitinib, at different doses, is effective for adults with moderate-to-severe atopic dermatitis who haven't responded well to dupilumab. It involves two periods: in the first period, participants receive either upadacitinib 15mg or dupilumab 300mg; if they respond well to upadacitinib 15mg, their dose may be increased to upadacitinib 30mg. In the second period, participants continue on their assigned treatment or are reassigned based on their response to eczema.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Dupilumab 300mg Dose
- 2.Take Upadacitinib 15mg Dose
- 3.Take Upadacitinib 30mg Dose
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
oral (Oral Solution)
Secondary: Participants who simultaneous achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1), Percentage of participants achieving worst pruritus numerical rating scale (WP-NRS) 0/1, Percentage of participants who achieve a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1)
Dermatology